Purpose: This retrospective study was undertaken to investigate the impact of initial gefitinib
or erlotinib (EGFR tyrosine kinase inhibitor, EGFR-TKI) versus chemotherapy on the risk of …

Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …

BACKGROUND: We investigated the risk of central nervous system (CNS) failure after
clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) …

Introduction: Brain metastases (BM) are common in advanced non-small cell lung cancer
(NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the …

Non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor
receptor (EGFR) mutation shows good and rapid response to EGFR tyrosine kinase …

Purpose Central nervous system (CNS) is the prevalent site for metastases in epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-relapsed NSCLC patients. To …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
been successfully used to treat patients with non-small cell lung cancer (NSCLC) harboring …

Introduction Epidermal growth factor receptor (EGFR) mutations in non–small-cell lung
cancers (NSCLC) may be more common in patients with brain metastases. Previous studies …

Objectives The purpose of this study was to examine the impact of EGFR mutations on the
incidence of brain metastases in patients with advanced non-small cell lung cancer …

e18065 Background: Some reports have showed that brain metastasis (BM) in the advanced
NSCLC patients has higher EGFR mutations. Gefitinib (TKI) has shown the effectiveness in …